Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Digital Pathology Systems Market to Reach US$1.4 Billion by the Year 2027

Published

on

New York, July 22, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Digital Pathology Systems Industry” – https://www.reportlinker.com/p05205340/?utm_source=GNW
9 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 13.9% over the analysis period 2020-2027.Device, one of the segments analyzed in the report, is projected to grow at a 13.8% CAGR to reach US$753.1 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software segment is readjusted to a revised 14.6% CAGR for the next 7-year period. This segment currently accounts for a 29.2% share of the global Digital Pathology Systems market.

The U.S. Accounts for Over 42.1% of Global Market Size in 2020, While China is Forecast to Grow at a 15.1% CAGR for the Period of 2020-2027

The Digital Pathology Systems market in the U.S. is estimated at US$241.7 Million in the year 2020. The country currently accounts for a 42.12% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$114.2 Million in the year 2027 trailing a CAGR of 15.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.9% and 12.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR while Rest of European market (as defined in the study) will reach US$114.2 Million by the year 2027.

Other Segments Segment Corners a 17.8% Share in 2020

In the global Other Segments segment, USA, Canada, Japan, China and Europe will drive the 12.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$86.6 Million in the year 2020 will reach a projected size of US$200.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$68.5 Million by the year 2027, while Latin America will expand at a 12.5% CAGR through the analysis period.

Select Competitors (Total 74 Featured)

  • 3DHISTECH Ltd.
  • Apollo Enterprise Imaging Corp.
  • Carl Zeiss AG
  • Corista LLC
  • Glencoe Software, Inc
  • Hamamatsu Photonics K.K.
  • Huron Digital Pathology, Inc.
  • Indica Labs
  • Inspirata Inc
  • KANTERON SYSTEMS S.L.U
  • KONFOONG BIOTECH INTERNATIONAL CO.,LTD
  • Leica Biosystems Nussloch GmbH
  • MikroScan Technologies
  • Inc.
  • Objective Pathology Services
  • Olympus Corporation
  • OptraSCAN, Inc
  • Philips Healthcare
  • Proscia Inc
  • Sectra AB
  • Visiopharm A/S

Read the full report: https://www.reportlinker.com/p05205340/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
COVID-19 Ushers in 2020 as the Year of Healthcare Digitalization
EXHIBIT 1: Global Venture Capital Investments in Digital Health
Startups (In US$ Billion)
EXHIBIT 2: % Share VC Investments by Category for 2020
FDA Temporarily Relaxes Guidelines to Promote Remote Digital
Pathology Services amid COVID-19 Pandemic
COVID-19 Highlights Need to Implement Structured Online
Curriculum for Pathology Training
Future Outlook of Pathology Post-COVID-19
Digital Pathology: An Introduction
Key Digital Pathology Tools
Market Outlook
US and Europe Maintain Dominance
Emerging Markets to Experience Strong Growth
Scanners Lead Digital Pathology Market
Software Segment Post Strong Growth
Disease Diagnosis: Major Application of Digital Pathology Systems
Telepathology Experiences Strong Growth
Pharmaceutical and Biotechnology Companies: Important End Use
Markets for Digital Pathology
EXHIBIT 3: Global Digital Pathology Systems Market by End-Use:
2020
Major Issues Hampering Adoption of Digital Pathology Systems
Competitive Landscape
EXHIBIT 4: Market Share of Leading Players in Digital Pathology
Systems Market: 2020E
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Technological Advancements Drive Adoption of Digital Pathology
Systems
Artificial Intelligence (AI) Steps in to Widen the Scope & Span
of Digital Pathology
EXIBIT: AI Spending in Healthcare & Lifesciences in US$ Million
for Years 2020 & 2025
Advantages of AI-Powered Digital Pathology
Digital Pathology Benefits Drug Discovery Process
Need for Early Diagnosis Puts Focus on Digital Pathology
Digital Pathology Systems See Fast Paced Adoption in Cancer and
Other Chronic Diseases
EXHIBIT 5: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 6: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018
EXHIBIT 7: Global New Cancer Cases and Cancer-related Deaths by
Cancer Site (in %) for 2018
Digital Pathology Emerges as a Tool to Reduce Cases of Cancer
Misdiagnoses
Scarcity of Pathologists & Excess Workload on Pathology Labs
Drives Demand for Digital Systems
Clinical Research Continues to be Core Vertical for Digital
Pathology
Digital Imaging and Robotic Light Microscopy Boost Growth
Computational Pathology for Leading-Edge Image Analytics
Cloud Platform Gains Momentum
Telepathology Expected to Pave Way for Pathology Outsourcing to
Developing Nations
Rise in Significance of Personalized Medicine Bodes Well for
Digital Pathology
EXHIBIT 8: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019 and 2024
Increased Focus on Companion Diagnostics to Benefit Market Growth
Improving Healthcare & Research Expenditure to Support Growth
EXHIBIT 9: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Aging Population: A Key Opportunity Indicator
EXHIBIT 10: Global Aging Population: Population of 65+
Individuals (in Thousands) by Region for 2019 and 2030
EXHIBIT 11: Global Population of 65+ Individuals as % of Total
Population by Region for 2019 and 2030
EXHIBIT 12: Global Cancer Deaths by Age Group (in %) for 2019
Challenges Facing Digital Pathology Systems Market
High Costs
Workflow Integration with Other Related Functions
Other Issues

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Digital Pathology
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Digital Pathology Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 3: World 12-Year Perspective for Digital Pathology
Systems by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2015,
2020 & 2027

Table 4: World Current & Future Analysis for Device by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Device by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 and
% CAGR

Table 6: World 12-Year Perspective for Device by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2015, 2020 & 2027

Table 7: World Current & Future Analysis for Software by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Software by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 and
% CAGR

Table 9: World 12-Year Perspective for Software by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2015, 2020 & 2027

Table 10: World Current & Future Analysis for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 12: World 12-Year Perspective for Other Segments by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027

Table 13: World Current & Future Analysis for Human Pathology
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Human Pathology by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 15: World 12-Year Perspective for Human Pathology by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027

Table 16: World Current & Future Analysis for Veterinary
Pathology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Veterinary Pathology by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 18: World 12-Year Perspective for Veterinary Pathology by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027

Table 19: World Current & Future Analysis for Pharma & Biotech
Companies by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Pharma & Biotech Companies
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 21: World 12-Year Perspective for Pharma & Biotech
Companies by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2015, 2020 &
2027

Table 22: World Current & Future Analysis for Hospitals &
Reference Labs by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals & Reference Labs
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 24: World 12-Year Perspective for Hospitals & Reference
Labs by Geographic Region – Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa for Years 2015, 2020 & 2027

Table 25: World Current & Future Analysis for Academic &
Research Institutes by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Academic & Research
Institutes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2015 through 2019 and % CAGR

Table 27: World 12-Year Perspective for Academic & Research
Institutes by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2015, 2020 &
2027

III. MARKET ANALYSIS

UNITED STATES
COVID-19 Triggers Demand for Digital Pathology
Market Overview
Increasing Pressure on Pathological Labs: Cornerstone for Growth
Table 28: USA Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Digital Pathology Systems by
Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 30: USA 12-Year Perspective for Digital Pathology Systems
by Segment – Percentage Breakdown of Value Sales for Device,
Software and Other Segments for the Years 2015, 2020 & 2027

Table 31: USA Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Digital Pathology Systems by
Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 33: USA 12-Year Perspective for Digital Pathology Systems
by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 34: USA Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 35: USA Historic Review for Digital Pathology Systems by
End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 36: USA 12-Year Perspective for Digital Pathology Systems
by End-Use – Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Hospitals & Reference Labs and Academic &
Research Institutes for the Years 2015, 2020 & 2027

CANADA
Table 37: Canada Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 39: Canada 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 40: Canada Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 42: Canada 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 43: Canada Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 45: Canada 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027

JAPAN
Market Overview
Table 46: Japan Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 48: Japan 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 49: Japan Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 51: Japan 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 52: Japan Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 53: Japan Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 54: Japan 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027

CHINA
Market Overview
Table 55: China Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 57: China 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 58: China Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 60: China 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 61: China Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 62: China Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 63: China 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027

EUROPE
Market Overview
Table 64: Europe Current & Future Analysis for Digital
Pathology Systems by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Digital Pathology Systems
by Geographic Region – France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets – Independent Analysis of
Annual Sales in US$ Thousand for Years 2015 through 2019 and %
CAGR

Table 66: Europe 12-Year Perspective for Digital Pathology
Systems by Geographic Region – Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2015, 2020 & 2027

Table 67: Europe Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 69: Europe 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 70: Europe Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 72: Europe 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 73: Europe Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 75: Europe 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027

FRANCE
Table 76: France Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 78: France 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 79: France Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 81: France 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 82: France Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 84: France 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027

GERMANY
Table 85: Germany Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 87: Germany 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 88: Germany Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 89: Germany Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 90: Germany 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 91: Germany Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 93: Germany 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027

ITALY
Table 94: Italy Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 95: Italy Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 96: Italy 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 97: Italy Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 98: Italy Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 99: Italy 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 100: Italy Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 102: Italy 12-Year Perspective for Digital Pathology
Systems by End-Use – Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027

UNITED KINGDOM
Table 103: UK Current & Future Analysis for Digital Pathology
Systems by Segment – Device, Software and Other Segments –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 104: UK Historic Review for Digital Pathology Systems by
Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 105: UK 12-Year Perspective for Digital Pathology Systems
by Segment – Percentage Breakdown of Value Sales for Device,
Software and Other Segments for the Years 2015, 2020 & 2027

Table 106: UK Current & Future Analysis for Digital Pathology
Systems by Type – Human Pathology and Veterinary Pathology –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 107: UK Historic Review for Digital Pathology Systems by
Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 108: UK 12-Year Perspective for Digital Pathology Systems
by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 109: UK Current & Future Analysis for Digital Pathology
Systems by End-Use – Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 110: UK Historic Review for Digital Pathology Systems by
End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 and % CAGR

Table 111: UK 12-Year Perspective for Digital Pathology Systems
by End-Use – Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Hospitals & Reference Labs and Academic &
Research Institutes for the Years 2015, 2020 & 2027

SPAIN
Table 112: Spain Current & Future Analysis for Digital
Pathology Systems by Segment – Device, Software and Other
Segments – Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 113: Spain Historic Review for Digital Pathology Systems
by Segment – Device, Software and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 114: Spain 12-Year Perspective for Digital Pathology
Systems by Segment – Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027

Table 115: Spain Current & Future Analysis for Digital
Pathology Systems by Type – Human Pathology and Veterinary
Pathology – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 116: Spain Historic Review for Digital Pathology Systems
by Type – Human Pathology and Veterinary Pathology Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 and % CAGR

Table 117: Spain 12-Year Perspective for Digital Pathology
Systems by Type – Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027

Table 118: Spain Current & Future Analysis for Digital
Pathology Systems by End-Use – Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Digital Pathology Systems
by End-Use – Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets – Independent

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05205340/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

First Comprehensive Report on Public Web Data Released by Bright Data

Published

on

first-comprehensive-report-on-public-web-data-released-by-bright-data

Reveals necessity in every industry
NEW YORK, April 23, 2024 /PRNewswire/ — Released today, The State of Public Web Data Report 2024, details a comprehensive analysis on how organizations leverage public web data to drive innovation, enhance customer experience, and develop AI models.

Bright Data commissioned an independent third-party to carry out the first survey of this kind which details the emergence of public web data as the most valued data type. Nearly every organization surveyed uses and benefits from public web data through quicker decision-making, boosting revenue, and meeting customer needs.
The need for public web data in AI is clear in all industries, with more than half of respondents using public web data to build AI models for customer service or to meet internal needs such as fraud detection and risk assessment.
Although necessary to build AI machines, 72% of respondents are worried that public web data will no longer be accessible in the next 5 years. The lack of a legal framework to protect this data emerged as a top concern.
Other key insights from the report:
89% of respondents recognize public web data is crucial or very important to the global economy.82% of respondents say public web data is critical to the future of their organization.79% of respondents agree that large organizations and or big tech hide too much of their public web data.88% of respondents believe public web data is critical for the development of AI models.”Our findings reveal a clear consensus among industry leaders: leveraging public web data is key to unlocking growth and fostering innovation,” said Or Lenchner, CEO of Bright Data. “Public web data is not a ‘like to have,’ it’s a ‘must have’ to conduct business and maintain a competitive market. We understand from our own experience with 20,000 customers that once a business realizes the potential of public web data they will look to discover new ways to leverage this tool to lead against the competition.”
About Bright Data: Bright Data is the #1 web data platform. Fortune 500 companies, academic institutions, non-profits, and small businesses rely on Bright Data’s solutions to collect public web data in the most efficient, reliable, and flexible way to make faster, more informed business-critical decisions.
Contacts:[email protected]
Logo – https://mma.prnewswire.com/media/2276620/Bright_Data_logo__1044x234_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/first-comprehensive-report-on-public-web-data-released-by-bright-data-302124673.html

Continue Reading

Artificial Intelligence

OSIA becomes an official International Telecoms Union (ITU) standard

Published

on

osia-becomes-an-official-international-telecoms-union-(itu)-standard

ITU Standardization Sector (ITU-T) Recommendation X.1281 – APIs for interoperability of identity management systems
BRUSSELS, April 23, 2024 /PRNewswire/ — The Secure Identity Alliance (SIA) announced today that its OSIA specification, is recognized as international standard by the International Telecommunication Union’s Telecommunication Standardization Sector (ITU-T). This milestone establishes OSIA as official ITU standard (ITU-T Recommendation) for the global infrastructure of information and communication technologies (ICT).

The specification that is now an ITU-T Recommendation is: ITU-T X.1281 – APIs for interoperability of identity management systems.
ITU-T is the standardization arm of ITU, the United Nations specialized agency for ICT. The Secure Identity Alliance specifications were approved as official ITU-T Recommendations by ITU members including 193 countries and the world’s front-running ICT companies on 1st March 2024. The new ITU-T Recommendation is under the responsibility of ITU’s standardization expert group for security, ITU-T Study Group 17.
“We are very proud that the OSIA specification is recognized as an international standard by ITU-T. This milestone demonstrates the maturity of OSIA and its potential to foster interoperability and promote fairness in the identity management systems market,” said Debora Comparin, Chair of the OSIA Initiative.
Prof. Heung Youl Youm, Chairman of ITU-T Study Group 17, said, “The recognition of the OSIA specification as an official ITU-T Recommendation underscores its critical contribution to the advancement of global ICT infrastructure. We are thrilled about the ongoing collaboration between ITU-T SG17 and the SIA, aimed at developing standards for secure identity management.”
“As Editor of the OSIA standard in the ITU-T Study Group 17 Q10, I am pleased to have contributed to this successful recommendation by the ITU,” said Abbie Barbir, Rapporteur for ITU-T’s working group on ‘Identity management and telebiometrics architecture and mechanisms’ (Q10/17). “The collaboration with the SIA continues on OSIA and other structuring initiatives and standards development.”
Engr Abisoye Coker-Odusote, CEO, National Identity Management Commission (NIMC), Nigeria & Chair of the OSIA Advisory Committee, said, “As the Chair of the OSIA Advisory Committee, comprised exclusively of government representatives, we take great pride in our five years of collaboration guiding the working group in the development of the OSIA specification. OSIA establishes equal marketplace conditions, fosters collaboration, and ensures product compatibility post-mergers and acquisitions. The OSIA standardized interfaces drive innovation, enabling new local market models and reducing fraud within multiple ID systems. Additionally, OSIA addresses integrator/vendor lock-in, allowing governments to maintain control over their identity systems and pursue national development agendas seamlessly.”
“The Secure Identity Alliance has always supported standards and its members have contributed to thousands of standards globally, which are now used in the ICT market. Standards are key to unlock the full power of Identity to enable people, economy and society to thrive,” concluded Didier Trutt, Chairman of the SIA.
X.1281 is at publication stage and can be accessed here: https://www.itu.int/ITU-T/workprog/wp_item.aspx?isn=18778
OSIA v6.1.0. twin specification can be accessed here: https://osia.readthedocs.io/en/v6.1.0/index.html 
OSIA qualification programme can be accessed here: https://globalplatform.org/osia-qualification-program/
For more information on the Secure Identity Alliance and the OSIA Initiative, visit http://www.secureidentityalliance.org and www.osia.io
For more information on ITU-T SG 17 visit https://www.itu.int/en/ITU-T/studygroups/2022-2024/17/Pages/default.aspx.
About the Secure Identity Alliance:
Secure Identity Alliance (SIA) is a global non-profit association that serves as the voice for public and private actors and organizations active in the secure identity ecosystem and adjacent industries. SIA’s mission is to unlock the full power of identity so that people, economy, and society thrive. The association supports the development of the activities of its members across four broad pillars: Identity for Good, Outreach, Open Standards Development and Industry Services and Solutions. www.secureidentityalliance.org
About OSIA:
A digital public good, OSIA is an open standard set of interfaces (APIs) that enables seamless connectivity between building blocks of the identity management ecosystem – independent of technology, solution architecture or vendor.  More information at www.osia.io
Follow the Secure Identity Alliance at on X @secureidentity1 and LinkedIn at https://www.linkedin.com/company/secure-identity-alliance/ 
About ITU-T SG 17
The ITU Telecommunication Standardization Sector (ITU-T) is one of the three Sectors (branches) of the International Telecommunication Union (ITU). It is responsible for coordinating standards for telecommunications and Information Communication Technology such as X.509 for cybersecurity, Y.3172 and Y.3173 for machine learning, and H.264/MPEG-4 AVC for video compression, between its Member States, Private Sector Members, and Academia Members.
Logo: https://mma.prnewswire.com/media/2394623/OSIA_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/osia-becomes-an-official-international-telecoms-union-itu-standard-302124668.html

Continue Reading

Artificial Intelligence

SciBase will present at the Redeye Medtech Event on April 24th

Published

on

scibase-will-present-at-the-redeye-medtech-event-on-april-24th

STOCKHOLM, April 23, 2024 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders will participate at the Redeye Medtech event.

On April 24 at CET 9.50 CEO Pia Renaudin will present the latest developments in SciBase at Redeye. The presentation is live broadcasted and can be followed at https://www.redeye.se/events/974326/redeye-theme-medtech-2 where the replay and the presentations will be available afterwards.
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/scibase-will-present-at-the-redeye-medtech-event-on-april-24-th-,c3966053
The following files are available for download:
https://mb.cision.com/Main/12371/3966053/2751965.pdf
Redeye presentation
 

View original content:https://www.prnewswire.co.uk/news-releases/scibase-will-present-at-the-redeye-medtech-event-on-april-24th-302124656.html

Continue Reading

Trending